ALS biomarker study aims to unlock disease clues

NCT ID NCT07260981

Completed Knowledge-focused Sponsor: Ulysses Neuroscience LTD Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed study looked at 60 people — 30 with ALS and 30 healthy volunteers — to measure immune system and nerve damage markers in their blood and spinal fluid. The goal was to better understand the role of a specific immune pathway (IFN-alpha) in ALS. By linking these markers to patient symptoms, researchers hope to find better ways to diagnose and track the disease, and to identify new targets for future treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this study could help identify biological markers that improve diagnosis or track ALS progression, and may support future development of treatments targeting the immune system.
What could go wrong: This is an observational biomarker study, not a treatment trial. It is small (60 participants) and completed, so it will not directly lead to a new therapy. Results may not apply to all ALS patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALS - AMYOTROPHIC LATERAL SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

amyotrophic lateral sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALS - AMYOTROPHIC LATERAL SCLEROSIS

Contacts and locations

Locations

Pioneer Life Sciences Cherrywood

Dublin, Ireland

More trials for these conditions

Other studies related to the condition(s) this trial covers.